{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:52Z","timestamp":1790963632621,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.phrs.2011.01.009","type":"journal-article","created":{"date-parts":[[2011,1,26]],"date-time":"2011-01-26T09:17:34Z","timestamp":1296033454000},"page":"423-431","source":"Crossref","is-referenced-by-count":52,"title":["Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome"],"prefix":"10.1016","volume":"63","author":[{"given":"F.","family":"Saint-Marcoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Guigonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gandia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ranchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Parant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bessenay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Libert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Harambat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bouchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Broux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Compagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Marquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.phrs.2011.01.009_bib0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/adc.57.7.544","article-title":"Long-term outcome of primary nephrotic syndrome","volume":"57","author":"Koskimies","year":"1982","journal-title":"Arch Dis Child"},{"issue":"5","key":"10.1016\/j.phrs.2011.01.009_bib0010","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","article-title":"Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children","volume":"8","author":"Tarshish","year":"1997","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.phrs.2011.01.009_bib0015","first-page":"239","article-title":"Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the International Study of Kidney Disease in Children","volume":"95","year":"1982","journal-title":"J Pediatr"},{"key":"10.1016\/j.phrs.2011.01.009_bib0020","first-page":"1","article-title":"Non-corticosteroid treatment for nephrotic syndrome in children","author":"Hodson","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.phrs.2011.01.009_bib0025","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncpneph1036","article-title":"An update on the use of mycophenoalte mofetil in lupus nephritis and other primary glomerular diseases","volume":"5","author":"appel","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"issue":"4","key":"10.1016\/j.phrs.2011.01.009_bib0030","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s00467-004-1778-4","article-title":"Switch from cyclosporine A to mycophenolate mofetil in nephrotic children","volume":"20","author":"Ulinski","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.phrs.2011.01.009_bib0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00467-003-1300-4","article-title":"Frequently relapsing nephritic syndrome: treatment with mycophenolate mofetil","volume":"19","author":"Gellermann","year":"2004","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1016\/j.phrs.2011.01.009_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00467-003-1175-4","article-title":"Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome","volume":"18","author":"Barletta","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"9","key":"10.1016\/j.phrs.2011.01.009_bib0045","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00467-005-1957-y","article-title":"Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome","volume":"20","author":"Novak","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"10.1016\/j.phrs.2011.01.009_bib0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00467-003-1174-5","article-title":"Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade","volume":"18","author":"Montan\u00e9","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"10.1016\/j.phrs.2011.01.009_bib0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5414\/CNP61025","article-title":"Mycophenolate mofetil in children with multidrug-resistant nephrotic syndrome","volume":"61","author":"Bayazit","year":"2004","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.phrs.2011.01.009_bib0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00467-006-0294-0","article-title":"A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome","volume":"22","author":"Fujinaga","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"10.1016\/j.phrs.2011.01.009_bib0065","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00467-007-0617-9","article-title":"Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome","volume":"22","author":"Afzal","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"10.1016\/j.phrs.2011.01.009_bib0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00467-003-1133-1","article-title":"Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children","volume":"18","author":"Filler","year":"2003","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.phrs.2011.01.009_bib0075","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.ajkd.2003.08.011","article-title":"Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome","volume":"42","author":"Bagga","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.phrs.2011.01.009_bib0080","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.00550206","article-title":"Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group","volume":"1","author":"Hogg","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.phrs.2011.01.009_bib0085","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00467-005-1877-x","article-title":"Mycophenolate mofetil in steroid\/cyclosporine-dependent\/resistant nephrotic syndrome","volume":"20","author":"Mendiz\u00e1bal","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"11","key":"10.1016\/j.phrs.2011.01.009_bib0090","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1007\/s00467-008-0899-6","article-title":"Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome","volume":"23","author":"Dorresteijn","year":"2008","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.phrs.2011.01.009_bib0095","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nephro.2005.06.003","article-title":"Corticosensitive nephrotic syndrome (or nephrosis) in children. Therapeutic guideline proposed by the Pediatric Society of Nephrology","volume":"1","author":"B\u00e9rard","year":"2005","journal-title":"Nephrol Ther"},{"issue":"8","key":"10.1016\/j.phrs.2011.01.009_bib0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","article-title":"A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil","volume":"44","author":"Pr\u00e9maud","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.phrs.2011.01.009_bib0105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.ftd.0000162231.90811.38","article-title":"Maximum a posteriori Bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods","volume":"27","author":"Pr\u00e9maud","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.phrs.2011.01.009_bib0110","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2165\/11317140-000000000-00000","article-title":"Pharmacokinetic modelling and development of Bayesian estimators for the therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic cell transplantation","volume":"48","author":"Saint-Marcoux","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"12 (December)","key":"10.1016\/j.phrs.2011.01.009_bib0115","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1007\/s11095-006-9116-0","article-title":"Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets","volume":"23","author":"Proost","year":"2006","journal-title":"Pharm Res"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2011.01.009_bib0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/03602538409015066","article-title":"Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model","volume":"15","author":"Steimer","year":"1984","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.phrs.2011.01.009_bib0125","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1002\/sim.1041","article-title":"Fisher information matrix for nonlinear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics","volume":"30","author":"Retout","year":"2002","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.phrs.2011.01.009_bib0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"10.1016\/j.phrs.2011.01.009_bib0135","first-page":"227","article-title":"Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis","volume":"36","author":"Debord","year":"1998","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.phrs.2011.01.009_bib0140","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1365-2125.2003.01863.x","article-title":"Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil","volume":"56","author":"Shum","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.phrs.2011.01.009_bib0145","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1681\/ASN.2005101070","article-title":"Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients","volume":"17","author":"van Hest","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.phrs.2011.01.009_bib0150","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2165\/0003088-200847120-00007","article-title":"Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients","volume":"47","author":"de Winter","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.phrs.2011.01.009_bib0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003088-200443040-00004","article-title":"Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients","volume":"43","author":"Le Guellec","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2011.01.009_bib0160","article-title":"Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches","author":"Pr\u00e9maud","year":"2010","journal-title":"Pharmacol Res"},{"issue":"4","key":"10.1016\/j.phrs.2011.01.009_bib0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2125.2010.03615.x","article-title":"Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephritic syndrome","volume":"69","author":"Zhao","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.phrs.2011.01.009_bib0170","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/01.ftd.0000159784.25872.f6","article-title":"Population pharmacokinetics of mycophenolic acid in kidney transplant pediatric and adolescent patients","volume":"27","author":"Payen","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.phrs.2011.01.009_bib0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1093\/clinchem\/41.7.1011","article-title":"Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics","volume":"41","author":"Nowak","year":"1995","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.phrs.2011.01.009_bib0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00007691-200406000-00011","article-title":"Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia","volume":"26","author":"Atcheson","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.phrs.2011.01.009_bib0185","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/FTD.0b013e3181ba9a0e","article-title":"High-performance liquid chromatography\u2013mass spectroscopy\/mass spectroscopy method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites","volume":"31","author":"Figurski","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.phrs.2011.01.009_bib0190","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00007691-200408000-00017","article-title":"Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient","volume":"26","author":"Mudge","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.phrs.2011.01.009_bib0195","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00007890-199804270-00019","article-title":"Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure","volume":"65","author":"Kaplan","year":"1998","journal-title":"Transplantation"},{"issue":"12 (June 27)","key":"10.1016\/j.phrs.2011.01.009_bib0200","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/TP.0b013e3181744199","article-title":"Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review","volume":"85","author":"Knight","year":"2008","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.phrs.2011.01.009_bib0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation","volume":"28","author":"van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.phrs.2011.01.009_bib0210","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2215\/CJN.07111009","article-title":"Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation","volume":"5","author":"Kuypers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.phrs.2011.01.009_bib0215","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.phrs.2011.01.009_bib0220","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.phrs.2009.09.006","article-title":"Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients","volume":"61","author":"Pr\u00e9maud","year":"2010","journal-title":"Pharmacol Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661811000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T02:32:16Z","timestamp":1637202736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661811000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1043661811000338"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2011.01.009","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}